[Treatment of metastatic non small cell lung cancer].
First line standard treatment of metastatic non-small-cell lung cancer is based on intravenous chemotherapy. Chemotherapy has been demonstrated to increase survival, to reduce symptoms and to improve quality of life. Bevacizumab, a monoclonal antibody inhibiting angiogenesis, improves survival when combined with chemotherapy. Because of a risk of hemoptysis, bevacizumab can only be delivered to non-squamous tumours with no proximal vascular invasion. Systemic treatment decision results from a multidisciplinary discussion and takes into account both patient (mostly performance status, age, and comorbidity) and tumour characteristics (histology, tumor location).
Westeel
Virginia
V
Service de pneumologie, hôpital Jean-Minjoz, université de Franche-Comté, 25030 Besançon Cedex. virginie.westeel@univ-fcomte.fr
Maître
Julien
J
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology* / Q000556:secondary / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*